Clinical Trials Logo
  1. Home
  2. Precancerous Conditions
  3. NCT04065737

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization — STOP  

Oral Cavity Cancer Clinical Trial

Official title:
A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization

Clinical Trial Summary

This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate how well sintilimab works in preventing high-risk oral premalignant lesions cancerization.

Clinical Trial Description

this study is a non-randomized, phase II, open-label study. Phase II clinical trials test the safety and effectiveness of an investigational drug or combination of drugs to learn whether it works in preventing or treating a disease.

the purpose of this study is to evaluate the effectiveness of sintilimab in preventing the onset of oral cancer in patients with high-risk oral premalignant lesions, who had oral cancer at least once before. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04065737
Study type Interventional
Source Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Contact Guopei Zhu
Phone +8602164175590
Email antica@gmail.com
Status Not yet recruiting
Phase Phase 2
Start date August 15, 2019
Completion date December 30, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT01695122 - Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Recruiting NCT01958762 - Screening for Cancers in the Oral CAvity N/A
Recruiting NCT05429099 - Mandibular Reconstruction Preplanning (ViPMR) Phase 2/Phase 3
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04809324 - Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Terminated NCT03555721 - CytID Analysis of Oral Lesions
Completed NCT01116843 - Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment Phase 1/Phase 2
Recruiting NCT05375266 - Immune Biomarker Study for Head and Neck Cancer
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT00359645 - Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population Phase 3
Completed NCT02412241 - Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients N/A
Terminated NCT00934739 - A Study of High-Risk Oral Cavity Cancer Phase 2/Phase 3
Not yet recruiting NCT06407570 - Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
Recruiting NCT05337631 - Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
Recruiting NCT05927220 - WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA
Recruiting NCT05369234 - Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis Phase 3